Argenica Therapeutics Limited (ASX:AGN)
Australia · Delayed Price · Currency is AUD 0.2800
+0.0100 (3.70%)
Jan 30, 2026, 3:34 PM AEST
Argenica Therapeutics Company Description
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia.
Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury.
The company was incorporated in 2019 and is based in Nedlands, Australia.
Argenica Therapeutics Limited
| Country | Australia |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Liz Dallimore |
Contact Details
Address: 117 Broadway Nedlands, Washington 6009 Australia | |
| Phone | 61 8 9329 3396 |
| Website | argenica.com.au |
Stock Details
| Ticker Symbol | AGN |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000150328 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Liz Dallimore B.Sc., M.B.A., Ph.D. | Chief Executive Officer, MD and Director |
| Emma Waldon | Chief Financial Officer and Company Secretary |
| Prof. Bruno Philip Meloni | Chief Scientific Officer |